Apicomplexa comprise a large phylum of single-celled, obligate intracellular protozoan organisms that all have a parasitic lifestyle. Among the more than 6000 named and probably more than one million unnamed species ¹ are some of great public health and economic relevance, since they cause severe diseases in humans and livestock, affecting millions each year ^{2– 6} . Therefore, increased knowledge about their biology in general, e.g. to exploit vulnerabilities, and their interaction with the host organism, e.g. to stimulate the immune system, is of great importance and promises major benefits in understanding and combating the diseases they cause. In addition, they possess a fascinating biology as intracellular eukaryotes thriving within another eukaryotic cell ( Figure 1), which clearly sets them apart from other pathogens like bacteria and viruses. Taken together, these are all good reasons to pay attention to these fascinating organisms. This review will focus on four important genera.

Plasmodium falciparum and four other Plasmodium species that affect humans cause malaria, a mosquito-transmitted, potentially deadly disease. According to the latest data from the World Health Organization (WHO), the number of deaths due to malaria has declined by 48% between 2000 and 2015 but the disease still causes the loss of ca. 438,000 lives each year of the 218 million people infected, mostly children under 5 years of age ⁵ .

An estimated one-third of the human population is chronically infected with Toxoplasma gondii leading to toxoplasmosis. It can cause severe symptoms in newborns (e.g. encephalitis and ocular disease) when a previously non-infected mother contracts the infection during pregnancy by ingesting infectious stages of T. gondii via contaminated food, water, or dust ⁷ . The latest numbers from WHO rank toxoplasmosis highest with respect to the overall lifelong disease burden among those foodborne diseases caused by protozoan parasites ⁸ .

The same study identified cryptosporidiosis (caused by two Cryptosporidium species, Cryptosporidium hominis and Cryptosporidium parvum) as the second most important disease in this class. Worldwide, each of these species infects 8–10 million people per year, but in addition they also cause considerable disease in livestock.

Lastly, Theileria parva, a tick-transmitted apicomplexan of ruminants, leads to the death of more than 1 million cattle per year in sub-Saharan Africa, causing costs of >300 million US$. This has severe socio-economic consequences for those regions ⁴ .

T. gondii, and to a lesser extent Plasmodium sp., has also gained increased attention from cell biologists owing to a number of unique mechanisms of host cell entry, division, motility, etc., thereby becoming model organisms for such aspects ⁹ . Both medical importance and model character are reflected by the overall citations in PubMed (several thousands from January 2013–December 2015 for the four taxa), making it impossible to cover even the most interesting discoveries of the last 2–3 years in all areas of apicomplexan research in reasonable depth. Consequently, only a few, admittedly subjective highlights in the fields of cell and molecular biology, biochemistry, and immunology as well as aspects concerning drugs will be mentioned here. These were selected because they are expected to make a major impact in the following years or offer explanations for puzzling unexplained observations in apicomplexan biology.

Many new findings require new technologies at first, and with the advent of next-generation sequencing (NGS) techniques ¹⁰ , the number and quality of apicomplexan genome sequences and respective transcriptomes have been growing considerably, allowing insights and discoveries that would have been hard or impossible to gain a few years ago ^{11– 13} . The genetic tools are most advanced for T. gondii and Plasmodium, and further specifics can be found in recent articles ^{14– 17} . Moreover, the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) genome editing system ¹⁸ and related techniques started a wave in 2012 ^{19, 20} that swept over the life sciences and since then has also reached the Apicomplexa. It has allowed targeted deletions, mutations, or gene additions so far in Plasmodium, T. gondii, and Cryptosporidium with unprecedented ease ^{21– 25} , as will be illustrated here for the latter.

Cryptosporidium sp. have some unique biological aspects within the phylum, which are of great evolutionary interest, like the presence of only a rudimentary mitochondrion (mitosome) or the absence of the secondary plastid called apicoplast ^{26, 27} . However, the lack of protocols for efficient long-term propagation in cell culture, reverse genetics, and thus methods to mark the parasites with fluorescent proteins has long precluded a broader analysis of many of those aspects. Application of CRISPR/Cas9, together with a number of smart optimizations of established techniques, plus the transfer of transfected parasites directly into the intestine of immune-deficient mice and their subsequent selection therein, changed the game ²² . This allowed for the first time the establishment of stably transfected C. parvum parasites and opens up a whole variety of options. For example, parasites expressing a reporter enzyme like luciferase will enable comprehensive drug screening efforts, allowing the tackling of an urgent need. Likewise, generation of genetically attenuated parasites by multi-gene deletions can be envisaged as a means to develop oral vaccines for livestock (or even humans). Effective vaccines for the former would minimize the contamination of the environment with excreted infectious oocysts. Finally, many fascinating cell biological aspects can now be followed and analyzed using fluorescent sporozoites.

In 2015, the Nobel Prize in Physiology or Medicine was in part awarded to Chinese scientist Youyou Tu for her major contributions to the discovery of artemisinin in the 1970s ^{28, 29} . It is the ingredient of a traditional Chinese herbal anti-malarial treatment that, when metabolized in situ to dihydroartemisinin, very efficiently kills Plasmodium sp.. Artemisinin combination therapies (ACTs) are currently the drugs of choice and recommended by WHO for treating P. falciparum infections worldwide, largely because drug resistance against other available compounds precludes their further use in many areas of Africa and South-East Asia (SEA) ³⁰ . ACTs consist of fast-acting artemisinin (or its derivatives) and less-potent, long-acting partner drugs. Artemisinin’s mode of action is unique in the sense that not a single protein or cell component but a multitude of parasite molecules are targeted by the compound via the generation of highly reactive endoperoxide-derived radicals ³¹ . These affect at least 124 parasites but few, if any, host proteins (at the level of currently applied experimental resolution), as a recent study reported ³² . This probably leads to the observed cellular stress response and increased molecular tagging of the affected proteins for disposal by the “cellular garbage can”, the proteasome ³³ . Many of these proteins are known or suspected to be essential for parasite growth, and their concerted damage by an unselective mechanism like oxidative damage could be expected to make it fairly difficult for the parasite to develop resistance (see below).

Only one plant is known to produce artemisinin, Artemisia annua L., and extraction yields do not exceed 0.5%. Therefore, the molecular deciphering of its biosynthesis ³⁴ and the subsequent biotechnological production of artemisinic acid, the key precursor from which artemisinin and other derivatives can be derived by straightforward chemical synthesis, was a major breakthrough ^{35, 36} . The genes required for this pathway were engineered into a yeast strain that can now produce artemisinic acid with a yield of 25 g/L of fermentation broth ³⁶ . Notably, although developed by a company, all intellectual property rights have been provided free of charge.

Unfortunately, this success story has recently been dampened by the emergence (again!) of resistance phenotypes in SEA ^{37, 38} . Resistance is defined as a parasite clearance half-life of at least 5 hours following ACT treatment, whereas non-resistant Plasmodium parasites are all killed earlier. The problem lies in the fact that delayed clearance (parasites are still killed, but slower) exposes the surviving organisms to the second drug in ACT, increasing the chance that resistance to this partner compound develops. Clearly, understanding the mechanism of artemisinin resistance is of utmost importance to be able to counteract and change drug regimens or composition.

Here, NGS and related techniques come into play. Sequencing resistant P. falciparum isolates directly from patients, a number of recent studies provided solid evidence for multiple mutations in a gene called kelch13 ( K13), which are associated with increased resistance ^{39– 42} . Transcriptomics identified an additional protein presumably involved, phosphatidylinositol-3 kinase (PI3K) ⁴³ (for details, see Figure 2).

Another transcriptomics study of 1000 (!) clinical P. falciparum isolates provided evidence that a population of parasites exists that is slowed down in growth and shows an upregulated so-called “unfolded protein response” pathway ⁴⁴ . This might allow parasites to repair proteins that were oxidatively damaged by artemisinin’s mode of action (see above) and progress through the rest of their lifecycle in red blood cells. The reduced growth would give them more time to do so. Puzzlingly, this report found no association between PI3K transcript levels and either parasite clearance half-life or K13 mutations. Evidently, more efforts are required to reconcile all the observations and to fully understand resistance development. Nevertheless, in a very short time, from the initial observation of delayed clearance times of ACT in SEA to the current studies, immense progress has been made in understanding the obviously very complex artemisinin resistance mechanism(s). Technological breakthroughs were just there at the right time to face this challenge.

Condensing parasitism to the meaning of the Greek word παράσιτος (parásitos; person who eats at someone else's table), and regarding biochemistry as the underlying science to reveal this eating behavior, there is an obvious and long-standing interest in understanding apicomplexan metabolism, not least because enzymes can make good drug targets ⁴⁵ . Again, technological advances in the field of metabolomics, together with gene knockouts, have greatly helped finding some answers to who eats what, when, and how.

Mitochondrial carbon metabolism in Apicomplexa is central to the generation of energy and several precursors of other pathways that occur outside the organelle, like pyrimidine and heme biosynthesis ^{46– 49} . One fundamental energy-generating system in most eukaryotes is the tricarboxylic acid (TCA) cycle in this organelle. It leads to complete oxidation of carbohydrates, lipids, and amino acids, thus allowing much greater ATP generation through the electron transport chain (ETC) than e.g. breakdown of glucose via glycolysis. T. gondii and Plasmodium sp. can get along with an energy supply derived only from glycolysis as long as they are living in glucose-rich environments. In fact, most (but not all) TCA cycle enzymes in P. falciparum could be knocked out with only little influence on the blood stage forms ⁵⁰ . Nevertheless, for a number of reasons, it seemed that a TCA cycle and ETC were operating in both organisms. For instance, several recent studies ^{50– 55} have shown that the development of Plasmodium berghei (a rodent model for P. falciparum) in the mosquito is not possible without a functional TCA cycle or ETC (summarized in 47). These studies have highlighted the great flexibility of both Plasmodium sp. and T. gondii with regard to substrate utilization and adaptation of carbon metabolism to different host environments.

However, an unresolved mystery was the experimentally well-proven absence of a key enzyme complex, pyruvate dehydrogenase (PDH), in the mitochondrion of Apicomplexa that would allow these organisms to feed glucose-derived pyruvate into the TCA cycle ^{47, 48} ( Figure 3a). This longstanding conundrum has now been solved, and it could be shown that a structurally related mitochondrial enzyme complex, branched-chain alpha-ketoacid dehydrogenase (BCKDH) usually involved in the degradation of branched-chain amino acids (BCAAs), has evolved to also take over the PDH task, generating acetyl-CoA from pyruvate ⁵¹ ( Figure 3a). Since pyruvate and the usual substrates for BCKDH are structurally quite similar ( Figure 3b), it is likely that only few (so far unknown) mutations were necessary to acquire the required substrate specificity. It is an illuminating example that holes in metabolic pathways predicted from genome data are not necessarily an annotation problem but can reflect evolutionary processes of reductive evolution ^{46, 48} .

Reductive evolution aims to reduce the considerable metabolic burden of gene and protein synthesis when the function of lost genes can be fulfilled otherwise ^{56, 57} . Importantly, in this case, parasitism wasn’t the driving force, since free-living dinoflagellates that share a common ancestor with Apicomplexa are also devoid of a mitochondrial PDH but possess BCKDH ⁴⁶ . Interestingly, while Plasmodium sp. have lost the entire BCAA degradation pathway of enzymes operating before and after BCKDH ^{46, 48} , thus saving even more on gene and protein synthesis, T. gondii as well as non-parasitic photosynthetic algae related to Apicomplexa have kept it ⁵⁸ .

One of the most fascinating aspects of the biology of Apicomplexa in general is their remarkable capacity to manipulate their respective host cells to suit their own demands. This causes changes in host cell signaling, nutrient delivery to the parasite, and evasion of host immunity ^{59– 62} . Amongst the many strategies leading to this outcome, unique examples are provided by T. parva and Theileria annulata.

Both species have the ability to immortalize (transform) their host cells, which resembles in many aspects cancerous cell transformation. T. parva transforms bovine B and T lymphocytes, whereas T. annulata, besides B cells, also transforms macrophages and dendritic cells ⁶³ . Activation of the c-Jun pathway, a signaling cascade involved in controlling many cellular processes including proliferation ⁶⁴ , has been shown previously to be required for Theileria-induced transformation ^{65, 66} . However, how this is accomplished at the molecular level has long been elusive.

Now, Marsolier et al. ⁶⁷ have reported the identification of a parasite-encoded enzyme called peptidyl-prolyl isomerase (PPIase), a homologue of human parvulin (hPIN1), as the transforming agent. Upon export into the host cell, the Theileria PPIase, like the human homolog, binds to a host protein (an ubiquitin ligase that controls the levels of c-Jun), leading to its destabilization and subsequent degradation. This in turn results in higher levels of c-Jun and eventually leads to cell transformation. These surprising findings go beyond parasite biology, as they also define prolyl-isomerization as a conserved mechanism that is important in cancer development.

T. gondii, amongst other Apicomplexa, is also a known expert in manipulation of the host cell at various levels via the secretion upon host cell entry of effector proteins ^{68, 69} , the number of which (currently around 80 ⁵⁸ ) is still increasing ^{70– 72} . The so-called rhoptry proteins (ROPs) are injected into the host cell cytosol during the actual invasion process via special organelles called rhoptries ⁷³ . A number of so-called GRA proteins derive from other organelles, the dense granules, and are delivered into the host cytosol after the parasite has formed its vacuole wherein it resides ⁷⁴ . Consequently, and in contrast to the ROPs, their mechanism of trafficking must include a way to pass this membrane structure. This aspect recently gained increased attention ⁷⁵ .

Precedence for this transport pathway came from the one that had been described for erythrocytic stages of Plasmodium. There, one molecular entity in the vacuolar membrane named “Plasmodium translocon of exported proteins” (PTEX) was recently described, which transports many parasite proteins into the cytosol of the red blood cell ^{76– 79} . Delivery to PTEX depends in turn on prior export of proteins out of the parasite cell into the vacuolar space, which requires cleavage by a specific protease (plasmepsin 5) at a particular sequence motif called “Plasmodium export element” (PEXEL) ⁷⁹ . This PEXEL motif allows the identification of many but not all proteins that are to be exported into the host cytosol ⁸⁰ .

It made sense to also look for such a motif in T. gondii – and it was found for numerous known GRA proteins ⁷⁵ . Now, several groups recently reported the importance of export of T. gondii aspartyl protease ASP5 (the homolog to plasmepsin 5 in Plasmodium), which resides in the parasite’s Golgi and processes those GRA proteins containing the PEXEL-like motif ^{70, 72, 81} . However, not all GRAs that depend on ASP5 for export contain a PEXEL-like motif. In Plasmodium, plasmepsin 5 is an essential gene already under in vitro growth conditions. This fact allowed the development of a very potent inhibitor of this crucial enzyme and that was subsequently used for structural studies ⁸² . In contrast, T. gondii parasites with a deleted ASP5 grow fine in cell culture but are much less virulent in a mouse model than the highly virulent parental strain. The very same phenotype has been described for a knockout strain of the ASP5-processed GRA14 ⁸³ . Together, this indicates the crucial importance of a repertoire of exported proteins during a natural infection. One reason for this might be the observed reduced migration of infected dendritic cells (which are known to be misused by T. gondii as Trojan horses to reach the brain ⁸⁴ ), thereby lowering the dissemination within the host ⁷² . Interestingly, this disparate phenotype upon gene deletion of in vitro and in vivo growth, together with a severe impact on protein export into the host, is shared with another recently reported T. gondii parasitophorous vacuolar membrane (PVM)-resident protein, Myc regulation 1 (MYR1) ⁸⁵ . Whether MYR1 is part of the T. gondii “translocon of exported proteins” needs to be determined, since e.g. Plasmodium sp. lack a homolog of MYR1. In addition, a T. gondii homolog of the putative PTEX pore protein EXP2 ⁸⁶ , GRA17, is involved in the translocation of only small molecules through the PVM but apparently not of proteins ⁸⁷ . This indicates that both species use very different molecular complexes for protein export into the host cell.

Another distinctive difference to Plasmodium sp. is that in the absence of ASP5, certain GRA proteins fail to be exported into the host’s cytosol and then further on into its nucleus. Here, they cause large disturbances in the transcriptome of the infected cell ^{70, 72} . Plasmodium sporozoites, the stage that infects hepatocytes, apparently do not possess dense granules ⁶¹ . Nevertheless, large transcriptomic changes in liver cells occur upon infection ⁸⁸ . Apparently, in both parasite species different effectors accomplish similar things, i.e. they modify their host cells to optimize their own survival therein.

The T. gondii studies further indicate that many more exported effector proteins besides the known ROPs and GRAs need to be identified to fully understand the ways this parasite manipulates its host cell. The ASP5 mutants will be a valuable source in this respect. More studies will be required to understand the details and evolution of this crucial mechanism in the Apicomplexa ⁸⁹ .

Innate immune responses are the immediate answer to an infection. They are triggered by the recognition of pathogen-derived molecules via evolutionarily conserved host receptors ⁹⁰ . In the last two decades, numerous studies found that innate sensing of apicomplexan infection is mediated by membrane-bound and cytoplasmic so-called pathogen recognition receptors (PRRs) such as Toll-like receptors (TLRs) and Nod-like receptors (NLRs) ^{91, 92} . Early sensing of infection by these pathways in antigen-presenting cells bridges the innate and adaptive immune responses by licensing them to interact with naïve, antigen-specific CD4 ⁺ and CD8 ⁺ T cells to stimulate them to become effector cells capable of producing cytokines and/or cytotoxic molecules. Efficient control of T. gondii and Plasmodium sp. infections is mediated by T and NK cell-derived interferon-gamma (IFN-γ) ^{93, 94} . This cytokine triggers the activation of very diverse effector pathways, e.g. NO production in infected host cells ⁹⁵ or induction of immunity-related GTPase (IRG) proteins (a family of rodent IFN-γ-induced GTPases) or GBP proteins (IFNγ-inducible guanylate-binding proteins) that damage the PVM ( Figure 1), thereby mediating parasite death ^{96– 101} . Recent studies emphasized the importance of GBP1 ¹⁰⁰ , GBP2 ¹⁰¹ , and the cooperation of IRGs with GBPs ⁹⁹ in cell-autonomous immunity and anti-parasitic resistance.

While the effects of IRGs on T. gondii in infected mice were known for some time, it became only recently apparent that laboratory mice and wild Mus musculus show enormous sequence diversity in particular genes of this family, with great and unexpected consequences for infection ¹⁰² . For decades, T. gondii strains were defined as being highly virulent in various strains of common laboratory mice because even a single parasite could kill them within days. Unexpectedly, those strains totally failed to reproduce this phenotype in wild mice. This is largely due to a highly polymorphic IRG allele that confers resistance against virulent parasites by interfering with their virulence factors of the ROP family of protein kinases ¹⁰² . The study is a striking example that lab mice and their wild counterparts can show very different responses to identical immunological challenges.

Protective immunity against T. gondii is governed by an IL-12-triggered Th1-type immune response, which involves NK cells, CD4 ⁺ effector cells, and CD8 ⁺ cytotoxic T cells as sources of IFN-γ ⁹³ . In order to induce its production by these cells, the innate arm of the immune system needs to sense the infection and relay this information into IL-12 production as an igniting factor for the ensuing Th1 response. Control of the infection is dependent on MYD88 ¹⁰³ , an adaptor molecule common to several TLRs, and the parasite-derived TLR-ligand T. gondii profilin ( TgPRF). The latter binds TLR11, which triggers a signaling cascade that stimulates IL-12 production by dendritic cells ^{59, 104} . However, TLR11 deficiency only modestly affects the survival of T. gondii-infected mice. Only recently was TLR12 shown to be involved in host resistance to T. gondii by recognizing TgPRF ¹⁰⁵ and cooperating with TLR11 to induce IL-12 in macrophages and dendritic cells ¹⁰⁶ .

Other studies demonstrate the involvement of additional pathogen-derived molecules and PRRs in starting an immune response by contributing to the stimulation of IL-12 production. A recent study employed mice carrying a mutation in UNC93B1, a molecule involved in subcellular trafficking of endosomal TLRs ¹⁰⁷ . These mice are highly susceptible to experimental toxoplasmosis and their phenotype is not recapitulated by mice deficient in nucleic acid sensing (TLR3-/TLR7-/TLR9-deficient) but rather by mice deficient in TLR7/TLR9 and TLR11, highlighting the redundancy of pathogen recognition in those animals ¹⁰⁸ ( Figure 4a). Humans lack TLR12 and harbor TLR11 as a pseudogene but produce high levels of pro-inflammatory cytokines in response to live phagocytosed parasites and parasite RNA and DNA. Thus, nucleic-acid-sensing TLRs seem to be the PRR operating in both hosts ^{108, 109} , while recognition of TgPRF by the TLR11/12 pathway is most likely an adaptation of rodents being a major intermediate host for T. gondii ¹⁰⁹ .

In contrast to T. gondii, which can infect virtually any nucleated cell, Plasmodium sp. are restricted to infecting hepatocytes and erythrocytes. Upon injection of Plasmodium sporozoites by the mosquito vector into the skin of the host, they first migrate to the liver and invade hepatocytes where they massively replicate. Early work on innate sensing of Plasmodium revealed that hemozoin-containing parasite DNA is recognized by TLR9 and mediates proinflammatory cytokine production by dendritic cells ¹¹⁰ , but little was known about the hepatic immune response. Strikingly, and in stark contrast to the erythrocytic cycle, which causes the well-known malaria symptoms like recurrent fever, this initial contact between the parasite and its host cell is without clinical signs. This could be taken as evidence for an immunologically silent hepatic stage of the infection. However, recently it was shown that hepatocytes do respond to P. berghei sporozoite invasion with induction of a type I IFN response. Parasitemia in liver and red blood cells was increased and leucocyte recruitment was decreased in type I IFN receptor-deficient ( Ifnar ^-/-) mice, highlighting the important role of type I IFN at this early phase of infection ¹¹¹ . The authors proposed a mechanism involving sensing of Plasmodium RNA by the cytoplasmic RNA receptor Mda5 and signaling via the mitochondrial antiviral signaling protein (Mavs) and the transcription factors Irf3 and Irf7, finally leading to transcription of IFN-α and IFN-β ( Figure 4b). A potential link among IFN-α, cell recruitment, and parasite elimination could be IFN-γ-secreting NK T cells, suggested by a recent study using the related species Plasmodium yoelii ¹¹² . However, a successful immune response often comes at a price, since a type I IFN response also causes malaria-associated immunopathology, such as liver damage and brain pathology ^{113, 114} .

Obviously, we could give only a subjective glimpse of the recent exciting developments in understanding apicomplexan biology. What will come next?

One can probably barely overestimate the impact that CRISPR/Cas9 technology will have on Apicomplexa research. It is expected that genome-wide CRISPR/Cas9 gene knockouts, similar to what has been described for mammals ¹¹⁵ , will also be published soon for Apicomplexa (preliminary data have been reported already for T. gondii ¹¹⁶ ). This will allow researchers to qualify genes as being either essential or not under different in situ conditions and to discover so far unknown phenotypes. For instance, parasites deficient in molecules known to target the innate immune system (but also knockdown of host PRRs, especially in primary human cells) will reveal pathways that are necessary for innate sensing and hence parasite control in rodents and humans and help to answer the question of whether actual infection, phagocytosis, or mere contact (“kiss and spit”) is required for CD4 ⁺ and CD8 ⁺ T cell responses.

Moreover, microscopy-based genome-wide screens on CRISPR/Cas9-generated knockouts or fluorescently tagged proteins can be envisaged to follow ¹¹⁷ . It would allow testing for function and localization of proteins that could not be achieved with this precision, speed, and coverage so far.

In particular, the less-studied stages (e.g. sexual stages within the mosquito [ Plasmodium] or the cat [ T. gondii]) will be of scientific interest. For the latter, establishing feline organoid cultures that would allow in vitro culture of the sexual stages will be crucial ¹¹⁸ . One of the most eminent questions in this respect is why does sex only take place in cats when this parasite is otherwise so extremely promiscuous in its host range? Together with the advent of modern metabolomics and gene knockouts, the answer to this and other questions might be within reach in the next few years.

Since Apicomplexa are pathogens, the development of new drugs and drug target candidates will of course remain a major driver for studying these parasites, and it is inevitable that there will be a big gain in understanding of the underlying molecular processes. Recent studies on crucial metabolic pathways for lipids ^{119, 120} , sugars ¹²¹ , and isoprenoids ¹²² have shown more potential metabolic vulnerabilities of apicomplexan parasites. Moreover, a new class of highly active anti-malarial compounds has already been described ^{123, 124} , and one of them, the spiroindolone KAE609, has shown very promising results in recent phase II clinical trials against uncomplicated malaria ^{125– 127} . Although drug resistance in the laboratory has already been described for spiroindolones, knowledge about its reported mechanism ^{123, 128, 129} will hopefully help in designing strategies to pre-emptively delay the spread of resistance in nature once KAE609 has been brought onto the market. However, the race is bound to start all over again – winner currently unknown.

ACTs, artemisinin combination therapies; BCAA, branched-chain amino acid; ASP5, aspartyl protease 5; BCAT, branched-chain amino acid transferase; BCKDH, branched-chain alpha-ketoacid dehydrogenase; CRISPR, Clustered Regularly Interspaced Short Palindromic Repeats; Cas, CRISPR associated; ETC, electron transport chain; hPINI, human parvulin; IFN-γ, interferon-gamma γ; IFNα/β, interferon α/β; IRG, immunity related GTPases; K13, kelch13; Mavs, mitochondrial antiviral signaling protein; MC, 2-methylcitrate; MYR1, Myc regulation 1; NGS, next-generation sequencing; NOD, Nod-like receptor; PDH, pyruvate dehydrogenase; PEXEL, Plasmodium export element; PI3K, phosphatidylinositol-3-kinase; PI3P, phosphatidylinositol-3-phosphate; PPIase, peptidyl-prolyl isomerase; PRR, pathogen recognition receptor; PTEX, Plasmodium translocon of exported proteins; PVM, parasitophorous vacuolar membrane; ROPs, rhoptry proteins; SEA, South-East Asia; TCA, tricarboxylic acid; TgPFR, Toxoplasma gondii-derived protein profilin; TLR, Toll-like receptor.

Dedicated to the memory of Klaus Lingelbach, a devoted Plasmodium scientist and a mentor of Frank Seeber.